


# The specialists in dental anaesthetics



# Pain control experts

We produce and inspect up to 1 million cartridges every day, shipping worldwide.

EU GMPs and European Pharmacopoeia compliant, Inibsa ranks among the top 3 manufacturers of dental anaesthetics worldwide.

Our dental cartridges are manufactured according to the highest quality standards and go through a complex automated production process in a sterile environment before finding their way to you.

## Our highlights

- Strong focus on local anaesthetics and sterile injectables products
- Top 3 manufacturers of dental cartridges worldwide
- Cutting-edge technology and equipments
- Highest standards of quality
- Products in +60 countries



**A complete range of dental anaesthetics**

**A safer and more effective treatment**

**Painless dental experience for the patient**

**Increased patient satisfaction**



● Headquarters    ● Local branches    ● Distribution partners

## International expertise in dental cartridges

- **Europe:** 20 countries
- **Africa:** 16 countries
- **Middle East:** 6 countries
- **CIS&Central Asia:** 7 countries
- **Asia-Pacific:** 11 countries
- **America:** 1 country

# Your patient's comfort

## Our commitment

### Inibsa at a glance



World-class R&D and manufacturing facilities.



Continuous R&D investments to improve our products.



+90 pharmaceutical dossiers registered in the world.



Capacity of up to 1 million dental cartridges/day.



+70 years of experience.



Products in +60 countries.



+300 staff members.



4 different molecules:  
6 injectable anaesthetics  
& 1 topical anaesthetic.
















## PRODUCT CHARACTERISTICS

# Guaranteed quality and safety at your fingertips

## Inibsa cartridge colour codes

1	2	3	4
<b>LIDOCAINE / EPINEPHRINE</b>			
	Xilonibsa 2% 1:80,000		
<b>ARTICAINE / EPINEPHRINE</b>			
	Artinibsa 4% 1:100,000		
	Artinibsa 4% 1:200,000		
<b>MEPIVACAINE / EPINEPHRINE</b>			
	Scandinibsa 2% 1:100,000		
<b>MEPIVACAINE</b>			
	Scandinibsa 3%		
<b>BUPIVACAINE</b>			
	Inibsacain 0.5% 1:200,000		

1 Active pharmaceutical ingredient (API) 2 Product name

3 Brand colour (box) 4 Capsule colour (API-specific)



## ASEPTIC FILLING PROCESS

### QUALITY ASSURANCE

- Process recognised and endorsed by EU GMPs, European Pharmacopoeia.
- Ensures a Sterility Assurance Level (SAL) of  $10^{-6}$ , equivalent to that achieved with terminal sterilisation.

## GLASS CARTRIDGES

### SYNONYM FOR QUALITY

- Type I neutral borosilicate glass, hydrolytic resistance.
- Allows aspiration reflux to be observed.
- Inner and outer silicone coating for gentle gliding and higher break resistance.

## LATEX-FREE PLUNGER AND DIAPHRAGM

### PEACE OF MIND FOR THE DENTIST

- Minimise the risk of allergic reactions.



## SECONDARY PACKAGING

### EASY TO HANDLE, STORE AND RECYCLE

- Tamper-evident with thumb cut.
- Carton boxes of 50 or 100 cartridges.
- Tamper-proof, easy to inspect blister with 10 separated cartridges.



# Artinibsa 4% 1:100,000

4% Articaine HCl + Epinephrine 1:100,000

Rapid onset of action,  
increased duration.  
Optimise your procedures.



Increase the efficacy and duration of your procedures with articaine's pharmacological properties. Compared to other anaesthetics, its great liposolubility improves diffusion through soft and hard tissues.

Moreover, it enhances the duration of the anaesthetic effect for a better view of the surgical area.

**Brand names:**

ARTINIBSA, ARTIBSA, ARTIDENTAL, ARDANEST, DENTOCAINE & LONCARTI.

**Maximum recommended dose\***

Artinibsa 4% 1:100,000 — 7 cartridges (healthy 70-kg adult)  
Articaine HCl\*\* — 7 mg/kg, maximum 500 mg  
Epinephrine — 0.2 mg/appointment

\* The maximum recommended dose (MRD) of the solution that contains both the anaesthetic and vasoconstrictor is dependent upon which of the two active ingredients reaches its MRD first.<sup>1</sup>

\*\* Limiting active ingredient.

## **i INGREDIENTS**

Articaine HCl 4% + Epinephrine 1:100,000

Each ml contains:

- Articaine hydrochloride 40.00 mg
- Epinephrine tartrate 0.018 mg (equivalent to 0.01 mg epinephrine base)

## **o POTENCY<sup>1</sup>**

Articaine is 1.5 times more potent than lidocaine.

## **! INDICATIONS**

- Local anaesthesia (by infiltration and nerve block) in dentistry, during complicated procedures that require prolonged anaesthesia.

## **= DESCRIPTION<sup>2,3</sup>**

- Anaesthesia where intentional ischemia of the tissues is wanted (visualisation of the surgical field and less intraoperative bleeding).

## **✓ DURATION OF ACTION<sup>1,4</sup>**

Onset of action: ~2 min

Pulpal Anaesthesia: 60 - 75 min

Soft tissue: 180 - 360 min



# Artinibsa 4% 1:200,000

4% Articaine HCl + Epinephrine 1:200,000

Rapid onset of action,  
increased duration.  
Optimise your procedures.



Take advantage of a medium to long-lasting anaesthetic effect in a great variety of procedures. Articaine's protein binding combined with the vasoconstrictor effect of epinephrine in a 1:200,000 formulation ensures suitable duration and efficacy.

**Brand names:**

ARTINIBSA, ARTIBSA, ARTIDENTAL, ARDANEST, DENTOCAINE & LONCARTI.

**Maximum recommended dose\***

Artinibsa 4% 1:200,000 — 7 cartridges (healthy 70-kg adult)  
Articaine HCl\*\* — 7 mg/kg, maximum 500 mg  
Epinephrine — 0.2 mg/appointment

\* The maximum recommended dose (MRD) of the solution that contains both the anaesthetic and vasoconstrictor is dependent upon which of the two active ingredients reaches its MRD first<sup>1</sup>.

\*\* Limiting active ingredient.

## **i** INGREDIENTS

Articaine HCl 4% + Epinephrine 1:200,000

Each ml contains:

- Articaine hydrochloride 40.00 mg
- Epinephrine tartrate 0.009 mg (equivalent to 0.005 mg epinephrine base)

## **o** POTENCY<sup>1</sup>

Articaine is 1.5 times more potent than lidocaine.

## **!** INDICATIONS

- Local anesthesia (by infiltration and nerve block) in dentistry, during complicated procedures that require prolonged anaesthesia.

## **✓** DURATION OF ACTION<sup>1,4</sup>

Onset of action: ~2 min

Pulpal anaesthesia: 45 - 60 min

Soft tissue: 120 - 300 min

# Xilonibsa 2%

## 1:80,000

2% Lidocaine HCl + Epinephrine

The gold standard  
dental anaesthetic.



With Xilonibsa 2% you will get suitable ischaemia and an anaesthetic effect of medium duration. Due to its optimal epinephrine concentration and lidocaine's well-known profile, this is still one of the best choices in terms of anaesthesia for its great adaptability to a number of clinical procedures.

**Brand names:**

XILONIBSA, XYON & XION.

**Maximum recommended dose\***

Xilonibsa 2% 1:80,000 — 8.8 cartridges (healthy 70-kg adult)  
Lidocaine HCl — 7 mg/kg, maximum 490 mg (healthy 70-kg adult)  
Epinephrine\*\* — 0.2 mg/appointment

\* The maximum recommended dose (MRD) of the solution that contains both the anaesthetic and vasoconstrictor is dependent upon which of the two active ingredients reaches its MRD first<sup>1</sup>.

\*\* Limiting active ingredient.

**i INGREDIENTS**

Lidocaine HCl 2% + Epinephrine 1:80,000

Each ml contains:

- Lidocaine hydrochloride 20.00 mg
- Epinephrine 0.0125 mg

**! INDICATIONS**

- Local dental anaesthesia by infiltration and nerve blockade.

**≡ DESCRIPTION**

- Dental procedures in pregnant women (FDA pregnancy classification B).

**✓ DURATION OF ACTION<sup>1</sup>**

Onset of action: 3 - 5 min

Pulpal anaesthesia: 60 min

Soft tissue: 180 - 300 min

# Xilonibsa Spray 10%

10% Lidocaine base

Fast and easy start.  
For painless local anaesthesia.



Offer your patients a fast and painless anaesthetic experience with Xilonibsa Spray 10%. This easy-to-apply local anaesthesia is indicated before starting your intraoral procedures.

## **i** ADMINISTRATION AND DOSAGE<sup>1,7,8</sup>

The dosage varies in accordance with the area to be anaesthetised, the extent of tissue vascularisation, individual tolerance, and the anaesthetic technique to be used.

- 1 to 5 applications on the mucosa.
- 3 sprays to the maxillary sinus puncture.
- Maximum of 20 pulses or 3 mg/kg of body weight per day, administering the lowest dose possible that provides the required anaesthetic effect.

Recommended administration: sprayed onto a dry mucous membrane.

## **i** INGREDIENTS

Each ml contains:

- Lidocaine 100 mg
- Ethanol 96°
- Menthol, saccharine, macrogol 400, banana flavouring and purified water.

## **!** INDICATIONS

Topical anaesthesia for mucous membranes in surgery, obstetrics, dentistry and otorhinolaryngology.

## **≡** DESCRIPTION<sup>5,6</sup>

Topical anaesthesia with lidocaine can be used in dentistry for:

- Desensitisation of the mucous membranes.
- Needle insertion for conduction or infiltration anesthesia.
- Control of pain in a wounded area.
- Placement of orthodontic bands.
- Inhibition of the pharyngeal reflex (for radiographic imaging or impression).
- Oral mucositis.
- Simple extraction of primary tooth.
- Dry socket.
- Rubber-dam clamp placement.
- Surgical treatment of the mucosal surface.
- Inhibition of reflexes during endotracheal intubation.
- Root planning or scaling.

## **✓** DURATION OF ACTION<sup>2</sup>

Onset of action: 1 - 3 min

Anaesthesia of the mucous membrane: 15 min

# Scandinibsa 2%

## 1:100,000

2% Mepivacaine HCl + Epinephrine 1:100,000

Intermediate-acting  
anaesthetic.



Offer your patients a local anaesthetic with lower vasodilating effect. Scandinibsa 2% with an associated vasoconstrictor is indicated for medium duration procedures. Its specific 1:100,000 formulation with epinephrine ensures suitable ischaemia during surgical procedures.

#### Maximum recommended dose\*

Scandinibsa 2% 1:100,000 — 5.5 cartridges (healthy 70-kg adult)  
1.5 cartridges (healthy 20-kg child)  
Mepivacaine HCl\*\* — 5 mg/kg, maximum 300 mg (healthy 70-kg adult)  
Epinephrine — 0.2 mg/appointment

\* The maximum recommended dose (MRD) of the solution that contains both the anaesthetic and vasoconstrictor is dependent upon which of the two active ingredients reaches its MRD first<sup>1</sup>.

\*\* Limiting active ingredient.

#### INGREDIENTS

Mepivacaine HCl 2% + Epinephrine 1:100,000

Each ml contains:

- Mepivacaine hydrochloride 20.00 mg
- Epinephrine tartrate 0.01 mg

#### POTENCY<sup>1</sup>

Mepivacaine is as potent as lidocaine.

#### INDICATIONS

- Local dental anaesthesia in adults, adolescents and children aged 4 years or older (20 kg body weight or higher).

#### DESCRIPTION

- Medium duration procedures for infiltration and nerve blockade anaesthesia.

#### DURATION OF ACTION<sup>1</sup>

Onset action: 2 - 3 min

Pulpal anaesthesia: 60 min

Soft tissue: 180 - 300 min

# Scandinibsa 3%

3% Mepivacaine HCl

A vasoconstrictor-free option for special patients.



Provide your patients with extra care and attention with Scandinibsa 3%. With its mild vasodilating effect, mepivacaine can be used without a vasoconstrictor, still offering great performance.

**Brand names:**

SCANDINIBSA & MEPIDENTAL.

**Maximum recommended dose\***

Scandinibsa 3% — 5.5 cartridges (healthy 70-kg adult)  
1.1 cartridges (healthy 20-kg child)

Mepivacaine HCl — 4.4 mg/kg, maximum 300 mg

## **i** INGREDIENTS

Mepivacaine HCl 3%

Each ml contains:

- Mepivacaine hydrochloride 30.00 mg

## **e** POTENCY<sup>1</sup>

Mepivacaine is as potent as lidocaine.

## **!** INDICATIONS

Local dental anaesthesia in adults, adolescents and children aged 4 years or older (20 kg body weight or higher).

## **≡** DESCRIPTION<sup>1</sup>

- Medium-short duration anaesthetic for infiltration and nerve blockade anaesthesia.
- Recommended for patients in whom a vasoconstrictor is contraindicated and for dental procedures not requiring lengthy or profound pulpal anaesthesia.
- Plain mepivacaine is commonly used in pediatric patients when the treating doctor is not a pediatric specialist (e.g., general practitioner) and is often appropriate in the treatment of geriatric patients.

## **✓** DURATION OF ACTION<sup>1,8</sup>

Onset of action: 3 - 5 min

Pulpal anaesthesia:

25 min - Maxillary infiltration

40 min - IANB

Soft tissue:

90 min - Maxillary infiltration

165 min - IANB



# Inibsacain 0.5% 1:200,000

0.5% Bupivacaine HCl + Epinephrine 1:200,000

Long-acting postoperative pain management.



Easily and safely manage postoperative pain with Inibsacain. This long-acting anaesthetic provides an effect of up to 12 hours. It is especially indicated for long and complex surgical procedures and ensures a painless postoperative experience for your patients.

#### Maximum recommended dose\*

Inibsacain 0.5% 1:200.000 — 10 cartridges (healthy 70-kg adult)  
Bupivacaine HCl\*\* — 1.3 mg/kg, maximum 90 mg  
Epinephrine — 0.2 mg/appointment

\* \* The maximum recommended dose (MRD) of the solution that contains both the anaesthetic and vasoconstrictor is dependent upon which of the two active ingredients reaches its MRD first<sup>1</sup>.

\*\* Limiting active ingredient.

#### INGREDIENTS

Bupivacaine HCl 0.5% + Epinephrine 1:200,000

Each ml contains:

- Bupivacaine hydrochloride 5.00 mg
- Epinephrine tartrate 0.009 mg (equivalent to 0.005 mg epinephrine base)

#### POTENCY<sup>1</sup>

Bupivacaine is 4 times more potent than lidocaine and mepivacaine.

#### INDICATIONS

Local anaesthesia induction for dental procedures in adults, by injection or trunk blockade.

#### DESCRIPTION<sup>9</sup>

- Long-lasting anaesthetic for postoperative pain management.
- Bupivacaine is frequently used for long-duration dental surgical procedures or where inflammation and pain are expected postoperatively.

#### DURATION OF ACTION<sup>1</sup>

Onset of action: 6 - 10 min

Pulpal anaesthesia: 90 - 180 min

Soft tissue: 240 - 540 min



## Bibliography

1. Malamed, S.F. Handbook of Local Anesthesia. 7th. ed.- St. Louis, MI : Elsevier Mosby, 2020. p. 64-75
2. Daskalov H. et al. Local anesthetics in patients with cardiovascular diseases. J of IMAB. 2015;21(1):728-731
3. Moore P.A. et al. Hemostatic and anesthetic efficacy of 4% articaine HCl with 1:200,000 epinephrine and 4% articaine HCl with 1:100,000 epinephrine when administered intraorally for periodontal surgery. J Periodontol. 2007;78(2):247-53.
4. Logothetis DD. Determining drug doses.- In: Local anaesthesia for the Dental Hygienist, 2021. 3th ed. - E-book.- p. 114-130
5. Quaba O. et al. A users guide for reducing the pain of local anaesthetic administration. Emerg Med J 2005; 22 (3):188-189
6. Lee HS. Recent advances in topical anesthesia. J Dent Anesth Pain Med. 2016; 16(4):237-244
7. Haddad F. Pain-reducing techniques for delivery of dental anesthesia. Dental Academy of Continuing Education. 2018
8. Summary of Product Characteristics of Artinibsa 4% 1:100,000, Artinibsa 4% 1:200,000, Xilonibsa 2% 1:80,000, Xilonibsa Spray 10%, Scandinibsa 20 mg/ml + 10 mcg/ml, Scandinibsa 3% and Inibsa 5 mg/ml + 0,005 mg/ml.
9. Gordon SM. et al. Long-acting local anesthetics and perioperative pain management. Dent Clin North Am. 2010 Oct;54(4):611-20



**Ctra. Sabadell a Granollers, Km. 14,5  
Lliçà de Vall, 08185. Barcelona (Spain)**

Email: [export@inibsa.com](mailto:export@inibsa.com)  
Tel.: +34 938 609 500  
Fax: +34 938 437 389

Scan me

